Natera Sees Deeper Operating Losses In Q2 On Higher Commercialization Costs For New Product Offerings

  • Natera Inc NTRA expects 2Q'21 revenues of approximately $138 million to $141 million, equivalent to around 60% Y/Y growth. 
  • The Company's revenue growth rate for the quarter would be the largest Y/Y growth in its history as a publicly traded company.
  • It sees Q2 product revenues of $135 million - $137 million vs. $80.4 million a year ago, representing approximately 70% Y/Y growth. 
  • Sequentially, the Company witnessed around an 8% fall in total sales of $152 million in Q1 2021.
  • Natera expects to recognize a loss from operations of approximately $113 million - $117 million for Q2 vs. a loss from operations of $51.7 million for 2Q 2020, reflecting the Company's increased R&D and SG&A costs in support of the commercialization of its new product offerings, which are expected to continue in subsequent quarters.
  • Loss from operations for Q1 of 2021 was $63.0 million.
  • In Q2, the Company processed approximately 370,000 tests, compared to about 234,000 tests last year. In Q1, Natera processed approximately 348,200 tests.
  • Price Action: NTRA shares are down 3.73% at $108.90 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!